On the other hand, anti-tumor necrosis factor (anti-TNF) drugs, while controlling IBD inflammation, may reduce the risk of NAFLD by improving systemic inflammatory status (20). This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.